ECSP13012766A - Comprimido farmaceutico de liberación controlada para administración oral - Google Patents

Comprimido farmaceutico de liberación controlada para administración oral

Info

Publication number
ECSP13012766A
ECSP13012766A ECSP13012766A ECSP13012766A EC SP13012766 A ECSP13012766 A EC SP13012766A EC SP13012766 A ECSP13012766 A EC SP13012766A EC SP13012766 A ECSP13012766 A EC SP13012766A
Authority
EC
Ecuador
Prior art keywords
oral administration
controlled release
compressed pharmaceutical
pharmaceutical controlled
active substance
Prior art date
Application number
Other languages
English (en)
Inventor
Paniagua Angélica Arzola
Hernandez Gustavo Barranco
Arroyo Héctor Senosiain
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46245166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012766(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Publication of ECSP13012766A publication Critical patent/ECSP13012766A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

La presente invención se refiere a composiciones farmacéuticas en forma de comprimidos para administración oral, que contienen principio activo y excipientes farmacéuticamente aceptables. Los comprimidos se caracterizan porque una parte del principio activo se libera en forma inmediata y otra parte del principio activo se encuentra en un sistema matricial polimérico y de difusión que permite liberar el principio activo de manera retardada.
ECSP13012766 2010-12-17 2013-07-15 Comprimido farmaceutico de liberación controlada para administración oral ECSP13012766A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2010014153A MX2010014153A (es) 2010-12-17 2010-12-17 Comprimido farmaceutico de liberacion controlada para administracion oral.

Publications (1)

Publication Number Publication Date
ECSP13012766A true ECSP13012766A (es) 2013-09-30

Family

ID=46245166

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012766 ECSP13012766A (es) 2010-12-17 2013-07-15 Comprimido farmaceutico de liberación controlada para administración oral

Country Status (11)

Country Link
BR (1) BR112013014963A2 (es)
CL (1) CL2013001707A1 (es)
CO (1) CO6721021A2 (es)
CR (1) CR20130288A (es)
DO (1) DOP2013000136A (es)
EC (1) ECSP13012766A (es)
GT (1) GT201300154A (es)
MX (1) MX2010014153A (es)
PE (1) PE20140675A1 (es)
RU (1) RU2603469C2 (es)
WO (1) WO2012080984A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016058813A1 (en) 2014-10-16 2016-04-21 Koninklijke Philips N.V. Aligning a patient within an mr scanner

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119627A (en) * 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030133982A1 (en) * 2001-12-20 2003-07-17 Heimlich John M. Zero-order sustained release dosage forms and method of making same

Also Published As

Publication number Publication date
CR20130288A (es) 2013-08-13
RU2603469C2 (ru) 2016-11-27
CL2013001707A1 (es) 2014-01-10
GT201300154A (es) 2014-05-07
RU2013127408A (ru) 2015-01-27
MX2010014153A (es) 2012-06-18
BR112013014963A2 (pt) 2016-09-13
WO2012080984A2 (es) 2012-06-21
DOP2013000136A (es) 2013-10-15
WO2012080984A3 (es) 2012-08-16
PE20140675A1 (es) 2014-06-25
CO6721021A2 (es) 2013-07-31

Similar Documents

Publication Publication Date Title
CR11709A (es) Preparacion solida de desintegracion oral
PE20142192A1 (es) Forma de dosificacion farmaceutica que comprende nifedipino o nisoldipino y un antagonista de angiotensina ii y/o diuretico
GT200600445A (es) Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo.
CL2013000424A1 (es) Forma de dosificacion farmaceutica resistente al rompimiento que comprende a) un ingrediente farmacologicamente activo, b) un polimero, c) un oxido de polialquileno, donde a) esta presente en una matriz de liberacion controlada que comprende b) y c).
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
CO6311067A2 (es) Preparación de comprimido con liberación retardada que contiene polivinilpirrolidonas y principio activo
IN2015DN03984A (es)
TN2015000135A1 (en) Modified release formulations for oprozomib
CO6640305A2 (es) Elaboración de gránulos sin activos y tabletas que comprenden los mismos
HK1218884A1 (zh) 用於在口腔中釋放至少種活性藥物成分的固體藥物劑型
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
MY152951A (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
MX353623B (es) Sistema de suministro de farmaco.
PE20131035A1 (es) Formulacion de nevirapina de liberacion prolongada
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
AR080256A1 (es) Formulaciones farmaceuticas solidas de ramipril y besilato de amlodipino y su preparacion
ECSP13012766A (es) Comprimido farmaceutico de liberación controlada para administración oral
TR201803451T4 (tr) Olmesartan formülasyonlari.
WO2013054178A3 (en) Extended release pharmaceutical compositions containing carmabazepine
UA105513C2 (uk) Лікарська форма уповільненого вивільнення глюкозаміну
UA110792C2 (uk) Лікарська форма бендамустину для перорального застосування
UA97982U (uk) Лікарський засіб седативної дії у вигляді таблеток
CU20130165A7 (es) Liberación modificada de 4-metil-3-[[-4-(3- piridinil)-2-pirimidinil]amino]-n-5-(4- metil-1h-imidazol-1- il)-3- (trifluorometil) fenil] benzamida solubilizada utilizando acidos orgánicos
IN2015MU00907A (es)